AstraZeneca’s Heart Failure Drug Wins EU Approval
AstraZeneca has won European Commission approval for Forxiga (dapagliflozin) for adult patients suffering from symptomatic chronic heart failure.
The approval was supported by phase 3 data demonstrating that, along with standard of care, Forxiga reduced worsening of heart failure events or death by 26 percent vs. placebo.
Forxiga is marketed as Farxiga in the U.S. The drug is also being reviewed for approval in Japan, among other countries.